Robert Siegel Presents Study on Oropharyngeal Cancer at ASCO

Authored by
Robert Siegel talking to a patient

In June 2018, before a room full of oncology experts, Robert Siegel, MD ’77, described a new treatment developed for patients suffering from oropharyngeal cancer.

Siegel, associate center director for education, training, and network development at the George Washington University (GW) Cancer Center, presented findings from a Phase II study during the American Society of Clinical Oncology’s Annual Meeting, held in Chicago.

Oropharyngeal cancer involves the base of the tongue, floor of the mouth, and tonsils, said Siegel. It’s not the most common cancer, but is also not a rare one, he noted.

“Historically, patients who develop this cancer have smoked heavily and consumed large amounts of alcohol," he said. However, now most oropharyngeal tumors are a consequence of human papillomavirus (HPV) infection; patients with HPV often have no history of heavy smoking or alcohol abuse. HPV tumors are more responsive to both chemotherapy and radiation, he added.

The current standard treatment includes a combination of high-dose radiation plus chemotherapy. Siegel noted that the treatment is “80 to 90 percent successful." However, the radiation leaves patients suffering from myriad side effects.

Short-term effects include damage to the back of the throat that makes eating painful, and often creates the need for gastrostomy tubes to maintain adequate nutrition. In the long term, radiation knocks out the salivary glands, leaving patients with chronic dry mouth, which can lead to increased gum and dental disease. The radiation can also alter a patient’s sense of taste and cause chronic swallowing problems.

The investigational treatment eliminates the need for radiation in most patients. Instead, said Siegel, patients receive three doses of standard chemotherapy followed by surgery.

“We found that the primary cancer and involved lymph nodes shrank dramatically with chemotherapy," he said. After chemotherapy treatment, the cancer was removed through a new technique - TORS (transoral robotic surgery). Siegel credited Nader Sadeghi, MD, a former faculty member, for bringing the technique to GW. Currently that technology is used by GW School of Medicine and Health Science head and neck surgeons Arjun Joshi, MD, associate professor of surgery; Punam Thakkar, MD, assistant professor of surgery; and Joseph Goodman, MD, assistant professor of surgery.

Siegel added that throughout the study, patients were referred to standard radiation therapy if the new treatment wasn’t working. “We were doing something unique, and we wanted to make it as safe as possible for the patients," he said.

Sixteen of the 20 patients in the study never needed radiation, and 18 of 20 patients remain in remission. “We saw at least equal effectiveness in the treatment, but were cutting way back on the side effects," Siegel said.

Siegel would like to add two more steps in a follow-up study: using next-generation sequencing of the tumor to identify which patients are at high risk for relapse, and incorporating additional drugs, such as immunotherapy drugs, to see if they would make the treatment even more effective.

Latest News

Lizie Sweeney has brains on the brain. More specifically, she has glioblastoma, a very aggressive form of brain cancer, at the front of her thoughts. As an Assistant Research Professor in the Department of Biochemistry and Molecular Medicine, she’s on a team researching novel therapies to treat…
Sherrie Flynt Wallington teaches GW School of Nursing students about health disparities. While many of them learn about healthcare inequities in the classroom, Sherrie learned about them first-hand in rural North Carolina, where she grew up.
NRG Oncology, a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced the appointment of Julie Bauman, MD, MPH as the new Chair of the organization’s Cancer…